Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared on LinkedIn.
”Osimertinib has changed the landscape for EGFR-mutated lung cancer, but its long-term heart safety has remained uncertain.
In our latest paper, we found that patients treated with osimertinib had higher rates of cardiomyopathy, ischemic heart disease, and heart failure compared with earlier-generation EGFR inhibitors. As survival improves, our findings highlight the need for ongoing cardiovascular monitoring to help prevent late toxicities.
Grateful to my outstanding co-authors Zaid Muhanna, Muntaser Zyoud, and Ahmad Issa three talented medical students I had the privilege to mentor on this project.”
Read the full Abstract here.
Stay updated with Hemostasis Today.
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026
-
Apr 2, 2026, 17:10Maxime Dely: Better Collection, Better Blood – The Quality Starts Now
-
Apr 2, 2026, 17:09Arun Danewa: Saving a Bone Marrow Patient from Hidden Enemy – TA-TMA
-
Apr 2, 2026, 17:07Cathy Harrison: The WFH Nurses Committee are Looking for New Members
-
Apr 2, 2026, 16:30Sam K. Saha: The Hardest Cases Are the Ones You Can’t Save
-
Apr 2, 2026, 16:20Veronica Sanchez: Know Stroke Signs and Act Fast
-
Apr 2, 2026, 16:08Ney Carter Borges: Early Surgery vs Conservative Care in Asymptomatic Very Severe Aortic Stenosis